WHG Helps Clients Develop and Execute Successful Health Policy Strategies to Maximize Enterprise Value - COVID-19 New Era & Beyond
- New CMS reimbursement pathways in aggregate with the newly formed Technology Coding and Pricing Group to allow for faster access to innovative technologies.
- New FDA Emergency Use Authorization (EUA) regulations to allow for commercialization of unapproved drugs and medical products or unapproved uses of approved drugs and medical products to be used in an emergency.
- New CDC public health guidance, evolving as the knowledge base grows, and expanded/refined data reporting.
- New NIH infectious disease research and expanded medical and behavioral health research.
|
WHG's innovative approach to health policy consulting and government relations is built on a two-step sequential process founded on 70+ years successful healthcare industry and government relations experience:
WHG provides clients a systematic and targeted engagement by working sequentially through interconnected groups of analytics to verify solid sustainable health policy strategies and reimbursement pathway tactics.
WHG's comprehensive reimbursement and market access pathways are founded on 70+ years healthcare industry and government relations experience.
|
|
Health Policy Challenges that Affect Reimbursement and Market Access
|
New FDA Emergency Use Authorization (EUA) regulations to allow for unapproved medical products or unapproved uses of approved medical products to be used in an emergency.
FDA approval and FDA clearance for non EUA medical products allows for commercialization. It does not mean that a product is covered or eligible for reimbursement by Medicare, Medicaid, or commercial insurance.
FDA approved indications for use and FDA product coding can result in downstream consequences with significant reimbursement pathway implications.
FDA controlled regulations affect CMS controlled policies determining site of care utilization, benefit category, coverage criteria and payment mechanisms.
Establishing new IPPS/HCPCS/CPT codes does not equate to CMS coverage or adequate payment, these reimbursement steps are separate CMS processes.
|
FDA regulations and CMS reimbursement processes are not intuitive and can lead to uncertainties and market access complications
WHG Core Set of Essential Strategy Analytics
|
Comprehensive Medicare, Medicaid and commercial insurance reimbursement pathway analysis.
Guidance through all 7-reimbursement steps - from diagnosis, treatment plan, site of care, and benefit category to coding, coverage and payment.
|
|
|
CMS utilization, mean costs and crosswalk data analytics are fundamental metrics of HHS and CMS decision-making trends.
CPT-RVU build up analysis - primary foundation of the annual Medicare Physicians Fee Schedule (MPFS) Rule Making process.
WHG categorizes the foundation of the hurdles identified in the 7-step reimbursement analysis and CMS analytics - executable milestones.
|
WHG identifies the current political and policy landscape
- Who can influence the change?
- What is the appetite for change?
Strategy analytics is the foundation for developing reimbursement pathways
WHG Focused Reimbursement Pathways
|
We identify the foundation of reimbursement hurdles or opportunities and prioritize executable milestones to maximize reimbursement:
|
|
We determine the pathway tactics once the actionable reimbursement strategies are defined and prioritized:
- Determine HHS and CMS policy jurisdiction
- Outline HHS and CMS decision-making processes
- Identify HHS and CMS key decision-makers and influencers
- Determine Capitol Hill policy jurisdiction, appropriations and oversight responsibilities
- Identify Capitol Hill key decision-makers and influencer
Are you Prepared for value-based payments? In the absence of evidence lower cost pressures will always prevail